A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls

Table 1 Characteristics of the included studies

Study	Country	Region	Sample size		Age (years)^a		Manufacturer of the OC assay kit	Target^b	Sampling condition	NOS^c
Study	Country	Region	PMO	Control	PMO	Control	Manufacturer of the OC assay kit	Target^b	Sampling condition	NOS^c
Zhang 2015	China	Asia	257	90	62.73 (3.94)	61.36 (3.75)	Roche	N-MID	NA	6
Al-Daghri 2014	Saudi Arabia	Asia	100	100	50.6 (8.2)	48.6 (7.3)	Roche	N-MID	fasting	9
Jabbar 2011	UK	Europe	185	185	62.06 (14.53)	62.56 (13.24)	Roche	N-MID	fasting	9
Verit 2006	Turkey	Europe	45	55	55.68 (5.58)	55.21 (6.21)	NA	NA	fasting	7
Pouilles 2006	France	Europe	60	120	52.2 (2.5)	52.2 (2.7)	Roche	N-MID	fasting	9
Luo 2006	China	Asia	45	44	56.1 (4.4)	55.6 (5.9)	DSL	intact	fasting	9
Duman 2004	Turkey	Europe	75	66	53.16 (1.31)	52.62 (1.69)	NA	NA	fasting	7
Dominguez 1998	Spain	Europe	26	17	59 (6)	56 (7)	Metra Biosystems	intact	fasting	7
Kim 1996	Korea	Asia	14	37	56.2 (1.7)	55.6 (1.3)	Incstar	NA	fasting	7
Diaz 1995	Spain	Europe	42	14	62 (11)	“paired”	Cis-bio	intact	fasting	7

OC osteocalcin, N-MID N-terminal midfragment of osteocalcin molecule, intact intact osteocalcin molecule, PMO postmenopausal osteoporosis, NOS Newcastle-Ottawa Scale, NA data not available. ^aAge is demonstrated with Mean (Standard deviation); ^bTarget fragment of the OC molecule; ^cRange: 1–9. Studies achieving six or more points are considered of high quality

ISSN: 1471-2474